Cogent Biosciences (COGT) Convertible Debt (2025 - 2026)
Cogent Biosciences (COGT) recorded quarterly Convertible Debt of $223.2 million in Q1 2026, little changed quarter-over-quarter from $222.9 million in Q4 2025.
Cogent Biosciences (COGT) Convertible Debt (2025 - 2026) Analysis & Trends
Cogent Biosciences' Convertible Debt history runs 2 years deep, the most recent figure standing at $223.2 million for Q1 2026.
- In Q1 2026, Convertible Debt changed N/A year-over-year to $223.2 million; the TTM figure through Mar 2026 stood at $223.2 million (changed N/A YoY), while the FY2025 annual figure was $222.9 million, changed N/A from the prior year.
- Convertible Debt was $223.2 million for Q1 2026 at Cogent Biosciences, roughly flat from $222.9 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $223.2 million in Q1 2026 to a low of $222.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 223.17 Mn |
| Dec 31, 2025 | 222.90 Mn |